Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $225 million of American Depositary Shares (“ADSs”) representing ordinary shares […]

by

Posted 01 November 2017 By Michael Mezher The US Food and Drug Administration (FDA) on Wednesday warned four companies selling cannabidiol (CBD) containing products for making claims that their products can treat or cure cancer and other diseases, including Alzheimer’s, arthritis, heart disease and stroke. “Selling these unapproved products with unsubstantiated therapeutic claims is not […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday’s pre-market session but then sold off after the opening bell. The company’s update on a clinical trial may have been overshadowed by GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s earnings […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

– Epidiolex® (cannabidiol) NDA Submitted to FDA –– Conference call today at 7:30 a.m. EST – LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial […]

by

U.S. Surgeon General Jerome Adams said medical marijuana should be studied and treated like other pain relief drugs but said he could not favor legalizing its recreational use. “Under medical marijuana, I believe it should be like any other drug,” Adams said Friday in Indianapolis. “We need to let the FDA vet it, study it, […]

by

While many cannabis cultivators utilize biological insects throughout their integrated pest management (IPM) programs, they also turn to biological pesticides and fungicides to combat and prevent outbreaks in their cultivation facilities. (In Colorado alone, there are just under 300 approved pesticides and fungicides available to cultivators for legal use within their growing operations, documents on […]

by

Posted 11 August 2017 By Zachary Brennan The US Food and Drug Administration (FDA) on Friday sought public comments to help prepare a response to the World Health Organization (WHO) regarding the abuse liability and diversion of 17 drug substances, many of which are opioids and similar to fentanyl. WHO will consider whether to recommend […]

by